Association Between Disease Activity and Ischaemia-modified Albumin in Patients with Ulcerative Colitis

Overview

Journal Prz Gastroenterol

Publisher Termedia

Specialty Gastroenterology

Date 2022 Sep 21

PMID 36127943

Authors

Serkan Ipek

Hulya Yalcin

Burak Toprak

Affiliations

Soon will be listed here.

Abstract

Introduction: An increased level of ischaemia-modified albumin (IMA) is not specific for cardiac ischaemia and has been shown to be elevated in many other conditions causing oxidative stress.

Aim: To assess the association between IMA and the disease activity in ulcerative colitis (UC), in which oxidative stress is thought to play a role in its pathogenesis.

Material And Methods: A total of 57 patients with ulcerative colitis (30 with active disease and 27 in remission) and 29 healthy controls were included in the study. IMA levels in those with active disease, those in remission, and healthy controls were compared. The correlations between IMA and other acute phase reactants were also assessed in the patient group.

Results: Significantly higher levels of IMA were found in patients with active UC as compared to those in remission and controls ( < 0.001). Patients in remission and control subjects did not differ significantly in terms of IMA levels. Also, IMA correlated with C-reactive protein and erythrocyte sedimentation rate, while it did not correlate with white blood cell count and platelet count.

Conclusions: Our results suggest that IMA, a marker of oxidative stress, may be a useful parameter for assessing the disease activity in patients with ulcerative colitis.

References

Pavlick K, Laroux F, Fuseler J, Wolf R, Gray L, Hoffman J . Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med. 2002; 33(3):311-22. DOI: 10.1016/s0891-5849(02)00853-5. View

Gidenne S, Ceppa F, Fontan E, Perrier F, Burnat P . Analytical performance of the Albumin Cobalt Binding (ACB) test on the Cobas MIRA Plus analyzer. Clin Chem Lab Med. 2004; 42(4):455-61. DOI: 10.1515/CCLM.2004.079. View

Bar-Or D, Curtis G, Rao N, Bampos N, Lau E . Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem. 2000; 268(1):42-7. DOI: 10.1046/j.1432-1327.2001.01846.x. View

Rezaie A, Parker R, Abdollahi M . Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?. Dig Dis Sci. 2007; 52(9):2015-21. DOI: 10.1007/s10620-006-9622-2. View

Ma S, Jin Y, Hu W, Bai F, Xu W, Yu W . Evaluation of ischemia-modified albumin and C-reactive protein in type 2 diabetics with and without ketosis. Biomark Insights. 2012; 7:19-26. PMC: 3308681. DOI: 10.4137/BMI.S9060. View

Apple F, Wu A, Mair J, Ravkilde J, Panteghini M, Tate J . Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005; 51(5):810-24. DOI: 10.1373/clinchem.2004.046292. View

Yang L, Ma S, Liu H, Xu W . Influence of obstructive sleep apnea on serum butyrylcholinesterase activity and ischemia-modified albumin levels. Clinics (Sao Paulo). 2013; 68(7):968-73. PMC: 3714914. DOI: 10.6061/clinics/2013(07)13. View

Sedghi S, Fields J, KLAMUT M, Urban G, Durkin M, Winship D . Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut. 1993; 34(9):1191-7. PMC: 1375452. DOI: 10.1136/gut.34.9.1191. View

Sbarouni E, Georgiadou P, Voudris V . Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med. 2010; 49(2):177-84. DOI: 10.1515/CCLM.2011.037. View

10.

Kruidenier L, Verspaget H . Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease--radicals or ridiculous?. Aliment Pharmacol Ther. 2002; 16(12):1997-2015. DOI: 10.1046/j.1365-2036.2002.01378.x. View

11.

Bar-Or D, Lau E, Winkler J . A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000; 19(4):311-5. DOI: 10.1016/s0736-4679(00)00255-9. View

12.

Kurien B, Scofield R . Free radical mediated peroxidative damage in systemic lupus erythematosus. Life Sci. 2003; 73(13):1655-66. DOI: 10.1016/s0024-3205(03)00475-2. View

13.

Shih D, Targan S, McGovern D . Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep. 2008; 10(6):568-75. PMC: 2734390. DOI: 10.1007/s11894-008-0104-x. View

14.

Chen C, Tsai W, Lin P, Shiesh S . The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med. 2011; 49(11):1817-21. DOI: 10.1515/CCLM.2011.675. View

15.

Lippi G, Montagnana M, Guidi G . Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia?. Int J Cardiol. 2006; 108(3):410-1. DOI: 10.1016/j.ijcard.2005.03.040. View

16.

Bouzid D, Gargouri B, Ben Mansour R, Amouri A, Tahri N, Lassoued S . Oxidative stress markers in intestinal mucosa of Tunisian inflammatory bowel disease patients. Saudi J Gastroenterol. 2013; 19(3):131-5. PMC: 3709376. DOI: 10.4103/1319-3767.111956. View

17.

Konikoff M, Denson L . Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12(6):524-34. DOI: 10.1097/00054725-200606000-00013. View

18.

Sklyarov A, Panasyuk N, Fomenko I . Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis. J Physiol Pharmacol. 2011; 62(1):65-73. View

19.

Powell S, Collier K, Reddy G, Cerchia R, Kahn E, Weissman G . Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996; 41(10):2078-86. DOI: 10.1007/BF02093613. View

20.

Gaze D . Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet. 2009; 24(4):333-41. DOI: 10.2133/dmpk.24.333. View